{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:22:20Z","timestamp":1786681340932,"version":"build-2736575974"},"reference-count":30,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2007,4,12]],"date-time":"2007-04-12T00:00:00Z","timestamp":1176336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Allergy"],"published-print":{"date-parts":[[2007,5]]},"abstract":"<jats:p>\n                    <jats:bold>Background:\u2002<\/jats:bold>\n                    Chronic urticaria is one of the most common and disturbing cutaneous condition. The treatment of chronic idiopathic urticaria (CIU) is still a challenge. Antihistamines are recommended as first\u2010line treatment. Rupatadine is a new potent nonsedative anti\u2010H\n                    <jats:sub>1<\/jats:sub>\n                    .\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Objective:\u2002<\/jats:bold>\n                    To study rupatadine efficacy and safety for moderate to severe CIU treatment.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:\u2002<\/jats:bold>\n                    This randomized, double\u2010blind, placebo\u2010controlled, parallel\u2010group, multicentre, study was designed to assess primarily mean pruritus score (MPS) reduction with rupatadine, 10 and 20\u2003mg, administered once daily for 4\u2003weeks. Three hundred and thirty\u2010three patients with active episodes of moderate\u2010to\u2010severe CIU were included.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:\u2002<\/jats:bold>\n                    A 57.5% (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003&lt;\u20030.005) and 63.3% (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003=\u20030.0001) significative MPS reduction from baseline, was observed at week 4 with 10 and 20\u2003mg rupatadine, respectively, compared with placebo (44.9%). Both doses of rupatadine were not significantly different at any time point, with respect to their effects on pruritus severity, number of wheals and total symptoms scores. Rupatadine 10\u2003mg had an overall better adverse event profile.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:\u2002<\/jats:bold>\n                    Rupatadine 10\u2003mg is a fast, long\u2010acting, efficacious and safe treatment option for the management of patients with moderate\u2010to\u2010severe CIU.\n                  <\/jats:p>","DOI":"10.1111\/j.1398-9995.2007.01330.x","type":"journal-article","created":{"date-parts":[[2007,4,12]],"date-time":"2007-04-12T11:19:52Z","timestamp":1176376792000},"page":"539-546","source":"Crossref","is-referenced-by-count":79,"title":["Rupatadine in the treatment of chronic idiopathic urticaria: a double\u2010blind, randomized, placebo\u2010controlled multicentre study"],"prefix":"10.1111","volume":"62","author":[{"given":"A.","family":"Gimenez\u2010Arnau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. M.","family":"Pujol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ianosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kaszuba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Malbran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Poop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Donado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Izquierdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Arnaiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Rupatadine Urticaria Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,4,12]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00130832-200310000-00008"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-0546(01)79045-3"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1997.d01-1168.x"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464220-00003"},{"key":"e_1_2_7_6_2","first-page":"119","article-title":"Review of H1 antihistamines in the treatment of chronic idiopathic urticaria","volume":"76","author":"Monroe E","year":"2005","journal-title":"Cutis"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07183.x"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.12.1343"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2005.00962.x"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(97)70026-5"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4684-5284-6_15"},{"key":"e_1_2_7_12_2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0022-3565(24)36413-4","article-title":"Ruptadine, a new potent, orally active dual antagonist of histamine and platelet\u2010activating factor (PAF)","volume":"280","author":"Merlos M","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_13_2","first-page":"161","article-title":"Inhibitory activity of rupatadine on pro\u2010inflammatory cytokine production, relationship with binding affinity","volume":"27","author":"Barr\u00f3n S","year":"2005","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"e_1_2_7_14_2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2340\/0001555570151153","article-title":"Effect of ceterizine on cutaneous reactions to PAF, kallikrein and serum in patients with chronic urticaria","volume":"70","author":"Juhlin L","year":"1990","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)61038-1"},{"key":"e_1_2_7_16_2","first-page":"22","article-title":"Rupatadine 10\u2003mg and cetirizine 10\u2003mg in seasonal allergic rhinitis: a randomised, double\u2010blind parallel group study","volume":"15","author":"Martinez\u2010Cocera C","year":"2005","journal-title":"J Investig Allergol Clin Immunol"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2004.00576.x"},{"key":"e_1_2_7_18_2","first-page":"34","article-title":"A randomized, double\u2010blind, parallel\u2010group study, comparing the efficacy and safety of rupatadine (20 and 10\u2003mg), a new PAF and H1 receptor\u2010specific histamine antagonist, to loratadine 10\u2003mg in the treatment of seasonal allergic rhinitis","volume":"14","author":"Saint\u2010Martin F","year":"2004","journal-title":"J Investig Allergol Clin Immunol"},{"key":"e_1_2_7_19_2","article-title":"Once\u2010daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomized, double\u2010blind, placebo\u2010controlled study","author":"Dubertret L","year":"2007","journal-title":"Eur J Dermatol"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)61466-4"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(99)70091-6"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62515-X"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2001.00186.x"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.143"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1996.tb00008.x"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.1999.00429.x"},{"key":"e_1_2_7_28_2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2340\/0001555572197200","article-title":"Effects of antihistamines on cutaneous reactions and influx of eosinophils after local injection of PAF, kallikrein, compound 48\/80 and histamine in patients with chronic urticaria and healthy subjects","volume":"72","author":"Juhlin L","year":"1992","journal-title":"Acta Derm Venerol"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198508153130702"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2005.00964.x"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2006.02278.x"}],"container-title":["Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1398-9995.2007.01330.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1398-9995.2007.01330.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T13:20:44Z","timestamp":1736947244000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1398-9995.2007.01330.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4,12]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["10.1111\/j.1398-9995.2007.01330.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1398-9995.2007.01330.x","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1086806.539730","asserted-by":"object"}]},"ISSN":["0105-4538","1398-9995"],"issn-type":[{"value":"0105-4538","type":"print"},{"value":"1398-9995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4,12]]}}}